492 related articles for article (PubMed ID: 24769013)
1. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
[TBL] [Abstract][Full Text] [Related]
2. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients.
Allinson K; Kolve H; Gumbinger HG; Vormoor HJ; Ehlert K; Groll AH
J Antimicrob Chemother; 2008 Mar; 61(3):734-42. PubMed ID: 18238891
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
4. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
5. [Effects of surgical resection of pulmonary lesions to the relapse of pulmonary aspergillosis in allogeneic hematopoietic stem cell transplant recipients with invasive pulmonary aspergillosis].
Gao L; Lin R; Sun J; Fan Z; Jiang Q; Huang F; Zhang Y; Zhou H; Dai M; Xu N; Liu Q
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):31-5. PubMed ID: 26796650
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
7. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
8. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Girmenia C; Barosi G; Piciocchi A; Arcese W; Aversa F; Bacigalupo A; Bandini G; Bosi A; Busca A; Castagnola E; Caselli D; Cesaro S; Ciceri F; Locasciulli A; Locatelli F; Mikulska M; Pagano L; Prete A; Raiola AM; Rambaldi A
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1080-8. PubMed ID: 24582783
[TBL] [Abstract][Full Text] [Related]
9. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
11. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
Liu M; Li Y; Zhang Y; Zhao X; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
PLoS One; 2014; 9(12):e115461. PubMed ID: 25531544
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
14. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
15. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
[TBL] [Abstract][Full Text] [Related]
16. Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients.
Piñana JL; Gómez MD; Montoro J; Lorenzo I; Pérez A; Giménez E; González-Barberá EM; Carretero C; Guerreiro M; Salavert M; Sanz G; Hernández-Boluda JC; Borrás R; Sanz J; Solano C; Navarro D
Transpl Infect Dis; 2019 Oct; 21(5):e13158. PubMed ID: 31402532
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
[TBL] [Abstract][Full Text] [Related]
18. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
[TBL] [Abstract][Full Text] [Related]
19. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes.
Sun YQ; Liu ZY; Huang XJ; Yan CH; Xu LP; Zhang XH; Liu KY; Wang Y
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1158-1164. PubMed ID: 28390982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
